Greg Zapotoczny is a member of the Lee Laboratory at the Ellison Institute, where he specifically leads the AR Drug Development team. Dr. Zapotoczny is testing novel anti-androgens for prostate cancer therapy and developing new screening techniques for non-AR therapeutic targets. Additionally, he established a Genetic Engineering Group to facilitate CRISPR workflows at the Institute.
Dr. Zapotoczny earned his BS and MS in Microbiology from the University of Wroclaw (Poland). He received his PhD in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill and is currently enrolled in MS in Regulatory Management at USC. Outside of work, he is an avid hiker and ballroom dancer.
Cancer Cell Biology
Mechanisms of Acquired Drug Resistance